Literature DB >> 22238297

A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Hongxing Hu1, Jarrod Voss, Guoliang Zhang, Philippi Buchy, Teng Zuo, Lulan Wang, Feng Wang, Fan Zhou, Guiqing Wang, Cheguo Tsai, Lesley Calder, Steve J Gamblin, Linqi Zhang, Vincent Deubel, Boping Zhou, John J Skehel, Paul Zhou.   

Abstract

Influenza A virus infection is a persistent threat to public health worldwide due to its ability to evade immune surveillance through rapid genetic drift and shift. Current vaccines against influenza A virus provide immunity to viral isolates that are similar to vaccine strains. High-affinity neutralizing antibodies against conserved epitopes could provide immunity to diverse influenza virus strains and protection against future pandemic viruses. In this study, by using a highly sensitive H5N1 pseudotype-based neutralization assay to screen human monoclonal antibodies produced by memory B cells from an H5N1-infected individual and molecular cloning techniques, we developed three fully human monoclonal antibodies. Among them, antibody 65C6 exhibited potent neutralization activity against all H5 clades and subclades except for subclade 7.2 and prophylactic and therapeutic efficacy against highly pathogenic avian influenza H5N1 viruses in mice. Studies on hemagglutinin (HA)-antibody complexes by electron microscopy and epitope mapping indicate that antibody 65C6 binds to a conformational epitope comprising amino acid residues at positions 118, 121, 161, 164, and 167 (according to mature H5 numbering) on the tip of the membrane-distal globular domain of HA. Thus, we conclude that antibody 65C6 recognizes a neutralization epitope in the globular head of HA that is conserved among almost all divergent H5N1 influenza stains.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238297      PMCID: PMC3302345          DOI: 10.1128/JVI.06665-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Authors:  Thomas C Luke; Edward M Kilbane; Jeffrey L Jackson; Stephen L Hoffman
Journal:  Ann Intern Med       Date:  2006-08-29       Impact factor: 25.391

2.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

Review 3.  Avian influenza A (H5N1) infection in humans.

Authors:  John H Beigel; Jeremy Farrar; Aye Maung Han; Frederick G Hayden; Randy Hyer; Menno D de Jong; Sorasak Lochindarat; Thi Kim Tien Nguyen; Tran Hien Nguyen; Tinh Hien Tran; Angus Nicoll; Sok Touch; Kwok-Yung Yuen
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

4.  Oseltamivir resistance during treatment of influenza A (H5N1) infection.

Authors:  Menno D de Jong; Tan Thanh Tran; Huu Khanh Truong; Minh Hien Vo; Gavin J D Smith; Vinh Chau Nguyen; Van Cam Bach; Tu Qui Phan; Quang Ha Do; Yi Guan; J S Malik Peiris; Tinh Hien Tran; Jeremy Farrar
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

5.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

6.  Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast.

Authors:  Teng Zuo; Xuanling Shi; Zhonghua Liu; Linlin Guo; Qing Zhao; Tianxia Guan; Xianming Pan; Na Jia; Wuchun Cao; Boping Zhou; Mark Goldin; Linqi Zhang
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

7.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

8.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

9.  Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.

Authors:  Surender Khurana; Amorsolo L Suguitan; Yonaira Rivera; Cameron P Simmons; Antonio Lanzavecchia; Federica Sallusto; Jody Manischewitz; Lisa R King; Kanta Subbarao; Hana Golding
Journal:  PLoS Med       Date:  2009-04-21       Impact factor: 11.069

10.  Re-emergence of fatal human influenza A subtype H5N1 disease.

Authors:  J S M Peiris; W C Yu; C W Leung; C Y Cheung; W F Ng; J M Nicholls; T K Ng; K H Chan; S T Lai; W L Lim; K Y Yuen; Y Guan
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

View more
  34 in total

1.  Recombinant baculovirus displayed vaccine: a novel tool for the development of a cross-protective influenza H5N1 vaccine.

Authors:  Mookkan Prabakaran; Jimmy Kwang
Journal:  Bioengineered       Date:  2013-08-09       Impact factor: 3.269

2.  Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir.

Authors:  Huanhuan Ren; Guiqin Wang; Shuangshuang Wang; Honglin Chen; Zhiwei Chen; Hongxing Hu; Genhong Cheng; Paul Zhou
Journal:  MAbs       Date:  2016-05-11       Impact factor: 5.857

Review 3.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

4.  Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1.

Authors:  Pengfei Wang; Yanan Zuo; Jianfeng Sun; Teng Zuo; Senyan Zhang; Shichun Guo; Xuanling Shi; Mifang Liang; Paul Zhou; Linqi Zhang; Xinquan Wang
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

5.  Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin.

Authors:  Mengran Qian; Hongxing Hu; Teng Zuo; Guiqin Wang; Linqi Zhang; Paul Zhou
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

6.  Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor.

Authors:  Lihong Liu; Michael Wen; Qianqian Zhu; Jason T Kimata; Paul Zhou
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-07       Impact factor: 4.147

7.  Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies.

Authors:  Shuangshuang Wang; Huanhuan Ren; Wenbo Jiang; Honglin Chen; Hongxing Hu; Zhiwei Chen; Paul Zhou
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

8.  A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin.

Authors:  Xueyong Zhu; Yong-Hui Guo; Tao Jiang; Ya-Di Wang; Kwok-Hung Chan; Xiao-Feng Li; Wenli Yu; Ryan McBride; James C Paulson; Kwok-Yung Yuen; Cheng-Feng Qin; Xiao-Yan Che; Ian A Wilson
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.

Authors:  Lanying Du; Lei Jin; Guangyu Zhao; Shihui Sun; Junfeng Li; Hong Yu; Ye Li; Bo-Jian Zheng; Robert C Liddington; Yusen Zhou; Shibo Jiang
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 10.  Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses.

Authors:  Lanying Du; Ye Li; Jimin Gao; Yusen Zhou; Shibo Jiang
Journal:  Rev Med Virol       Date:  2012-09-14       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.